{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:55:38Z","timestamp":1770814538016,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100790","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T11:15:12Z","timestamp":1705058112000},"page":"100790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9172-9320","authenticated-orcid":false,"given":"Luiz Ricardo","family":"Soldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo Henrique","family":"Rabelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Henrique Rosa","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-5547","authenticated-orcid":false,"given":"Victor Luigi Costa","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Jos\u00e9 Barbosa","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2024.100790_bib0001","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.5858\/arpa.2015-0197-RAI","article-title":"Reed-Sternberg-Like Cells in Non-Hodgkin Lymphomas","volume":"139","author":"Gomez-Gelvez","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctarc.2024.100790_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2016-11-746701","article-title":"Exposing Hodgkin-Reed-Sternberg cells","volume":"129","author":"Steidl","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2024.100790_bib0003","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14737159.7.6.805","article-title":"Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed-Sternberg cell","volume":"7","author":"Roullet","year":"2007","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ctarc.2024.100790_bib0004","first-page":"7","article-title":"Cancer statistics,","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctarc.2024.100790_bib0005","article-title":"Estimativa\/2020 \u2013 Incid\u00eancia de C\u00e2ncer no Brasil","volume":"66","author":"de O. Santos","year":"2020","journal-title":"Revista Brasileira de Cancerologia"},{"key":"10.1016\/j.ctarc.2024.100790_bib0006","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10051125","article-title":"Hodgkin Lymphoma\u2014Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients","volume":"10","author":"Momotow","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctarc.2024.100790_bib0008","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2024.100790_bib0009","article-title":"Lugano staging classification","author":"Weerakkody","year":"2018","journal-title":"Radiopaedia.Org"},{"key":"10.1016\/j.ctarc.2024.100790_bib0010","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","article-title":"Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature","volume":"20","author":"Ambroggi","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2024.100790_bib0011","first-page":"5","article-title":"Advanced stage Hodgkin Lymphoma: patient management","volume":"91","author":"Gini","year":"2020","journal-title":"Acta Bio Medica\u00a0: Atenei Parmensis"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2024.100790_bib0012","article-title":"Mortality patterns in hypertension","volume":"29","author":"Arima","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.ctarc.2024.100790_bib0013","doi-asserted-by":"crossref","unstructured":"D. Zhou, B. Xi, M. Zhao, L. Wang, S.P. Veeranki, Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study, Sci Rep. 8 (2018) 9418. https:\/\/doi.org\/10.1038\/S41598-018-27377-2.","DOI":"10.1038\/s41598-018-27377-2"},{"key":"10.1016\/j.ctarc.2024.100790_bib0014","first-page":"246","article-title":"Hypertension in Patients with Cancer","volume":"104","author":"De Souza","year":"2015","journal-title":"Arq Bras Cardiol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100790_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-021-00101-2","article-title":"Etiology and management of hypertension in patients with cancer","volume":"7","author":"Mohammed","year":"2021","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.ctarc.2024.100790_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-016-1895-8","article-title":"The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: A Japanese retrospective study Urology","volume":"9","author":"Miyake","year":"2016","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.ctarc.2024.100790_bib0018","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","article-title":"Oxidative stress, inflammation, and cancer: How are they linked?","volume":"49","author":"Reuter","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ctarc.2024.100790_bib0019","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/healthcare10061074","article-title":"Association of Hypertension and Organ-Specific Cancer: A Meta-Analysis","volume":"10","author":"Connaughton","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.ctarc.2024.100790_bib0020","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0021","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctarc.2024.100790_bib0022","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0023","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc1109618","article-title":"ABVD versus BEACOPP for Hodgkin's Lymphoma","volume":"365","author":"Corazzelli","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctarc.2024.100790_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/485071","article-title":"The role of radiotherapy in Hodgkin's lymphoma: What has been achieved during the last 50 years?","author":"Witkowska","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ctarc.2024.100790_bib0025","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma - A report from the Children's Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctarc.2024.100790_bib0026","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1200\/JCO.2005.02.907","article-title":"ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi","volume":"23","author":"Gobbi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0027","doi-asserted-by":"crossref","DOI":"10.21037\/acr.2019.07.08","article-title":"Classic Hodgkin lymphoma with initial extranodal osseous presentation: a case report and literature review","volume":"3","author":"Gomez","year":"2019","journal-title":"AME Case Rep"},{"key":"10.1016\/j.ctarc.2024.100790_bib0028","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5732\/cjc.012.10008","article-title":"Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites","volume":"31","author":"Li","year":"2012","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.ctarc.2024.100790_bib0029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00432-004-0641-0","article-title":"Primary multifocal osseous Hodgkin disease: A case report and review of the literature","volume":"131","author":"Gebert","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1440-1673.1993.tb00011.x","article-title":"Bone involvement in Hodgkin's disease","volume":"37","author":"BORG","year":"1993","journal-title":"Australas Radiol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0031","first-page":"2079","article-title":"Extranodal presentation of hodgkin's lymphoma of the sternum: A case report and review of the literature","volume":"15","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctarc.2024.100790_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-6-34","article-title":"Primary multifocal osseous Hodgkin's lymphoma","volume":"6","author":"Langley","year":"2008","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0033","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3389\/fphar.2021.694545","article-title":"Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma","volume":"12","author":"Pei","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0034","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00277-008-0635-0","article-title":"Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study","volume":"88","author":"Souza","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/IJPC.IJPC_107_19","article-title":"Bleomycin in Hodgkin's Lymphoma \u2013 A Boon or a Bane? \u2013 A Retrospective Study of Bleomycin Pulmonary Toxicity in Hodgkin's Lymphoma","volume":"25","author":"Udupa","year":"2019","journal-title":"Indian J Palliat Care"},{"key":"10.1016\/j.ctarc.2024.100790_bib0036","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.critrevonc.2012.12.003","article-title":"Revisiting bleomycin from pathophysiology to safe clinical use","volume":"87","author":"Froudarakis","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0037","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/bi960092y","article-title":"Human Bleomycin Hydrolase: Molecular Cloning, Sequencing, Functional Expression, and Enzymatic Characterization","volume":"35","author":"Br\u00f6mme","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctarc.2024.100790_bib0038","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1128\/MCB.18.6.3580","article-title":"The nucleic acid binding activity of bleomycin hydrolase is involved in bleomycin detoxification","volume":"18","author":"Zheng","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0039","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/cells8091013","article-title":"Highlights in Resistance Mechanism Pathways for Combination Therapy","volume":"8","author":"Delou","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2024.100790_bib0040","first-page":"2013","article-title":"Bleomycin-induced lung injury","author":"Reinert","year":"2013","journal-title":"Downloads.Hindawi.Com"},{"key":"10.1016\/j.ctarc.2024.100790_bib0041","first-page":"14","article-title":"Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era","author":"Jennane","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ctarc.2024.100790_bib0042","article-title":"Pulmonary Toxicity of Bleomycin \u2013 A Case Series from a Tertiary Care Center in Southern India","volume":"10","author":"Patil","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.ctarc.2024.100790_bib0043","doi-asserted-by":"crossref","unstructured":"K. Taparra, H. Liu, M.Y. Polley, K. Ristow, T.M. Habermann, S.M. Ansell, Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era, https:\/\/doi.org\/10.1080\/10428194.2019.1663419. 61 (2019) 298\u2013308. https:\/\/doi.org\/10.1080\/10428194.2019.1663419.","DOI":"10.1080\/10428194.2019.1663419"},{"key":"10.1016\/j.ctarc.2024.100790_bib0044","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0045","doi-asserted-by":"crossref","unstructured":"H. (Linda) Sun, E.G. Atenafu, R. Tsang, V. Kukreti, T.K. Marras, M. Crump, J. Kuruvilla, Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma, https:\/\/doi.org\/10.1080\/10428194.2017.1307980. 58 (2017) 2607\u20132614. https:\/\/doi.org\/10.1080\/10428194.2017.1307980.","DOI":"10.1080\/10428194.2017.1307980"},{"key":"10.1016\/j.ctarc.2024.100790_bib0046","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrc1547","article-title":"Bleomycins: Towards better therapeutics","volume":"5","author":"Chen","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctarc.2024.100790_bib0047","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.athoracsur.2004.03.081","article-title":"Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy","volume":"78","author":"Andrade","year":"2004","journal-title":"Annals of Thoracic Surgery"},{"key":"10.1016\/j.ctarc.2024.100790_bib0048","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0022-5347(01)62533-3","article-title":"Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?","volume":"160","author":"Donat","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0049","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ctarc.2024.100790_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/480608","article-title":"Bleomycin-Induced Lung Injury","volume":"2013","author":"Reinert","year":"2013","journal-title":"Journal of Cancer Research"},{"key":"10.1016\/j.ctarc.2024.100790_bib0051","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"O'Sullivan","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0052","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctarc.2024.100790_bib0053","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.ctarc.2024.100790_bib0054","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jha2.1","article-title":"Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?","volume":"1","author":"Gunther","year":"2020","journal-title":"EJHaem"},{"key":"10.1016\/j.ctarc.2024.100790_bib0055","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0056","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0057","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2024.100790_bib0058","doi-asserted-by":"crossref","unstructured":"B. Journal of Hematology, R. Dezen Gaiolla, Hodgkin's lymphoma in developing countries: can we go further?\u2606, Rev Bras Hematol Hemoter. 39 (2017) 299\u2013300. https:\/\/doi.org\/10.1016\/J.BJHH.2017.08.004.","DOI":"10.1016\/j.bjhh.2017.08.004"},{"key":"10.1016\/j.ctarc.2024.100790_bib0059","first-page":"13","article-title":"Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era","volume":"8","author":"Lapuz","year":"2018","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.ctarc.2024.100790_bib0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.314.7077.343a","article-title":"Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records","volume":"314","author":"Radford","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2024.100790_bib0061","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.currproblcancer.2010.04.007","article-title":"ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma","volume":"34","author":"Ng","year":"2010","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2024.100790_bib0062","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer Journal"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:34:37Z","timestamp":1762842877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294224000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":62,"alternative-id":["S2468294224000029"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100790","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100790"}}